Guangzhou Lupeng Pharmaceutical Company LTD.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Rocbrutinib NCT05716087 |
P2 | Active, not recruiting | Mantle Cell Lymphoma (MCL) | 62 | 2024-12-05 (+9 mo) |
| Rocbrutinib NCT07189065 |
P2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 150 | 2027-12-31 |
| Lacutoclax NCT07609823 |
P2 | Recruiting | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 75 | 2028-03-30 |
| Rocbrutinib NCT07776743 |
P2 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 30 | 2028-06 |
| Lacutoclax+Rocbrutinib NCT07609862 |
P1/2 | Recruiting | Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL) | 92 | 2029-06-30 |
| Rocbrutinib NCT07377578 |
P3 | Recruiting | Mantle Cell Lymphoma | 394 | 2031-05-30 |